Anzeige
Erschienen in:
08.06.2018 | Position Paper
Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464)
Erschienen in: Osteoporosis International | Ausgabe 7/2018
Einloggen, um Zugang zu erhaltenAbstract
Purpose
To comment on the latest technology appraisal of the National Institute for Clinical Excellence (NICE) in osteoporosis.
Methods
Review of NICE Technology Appraisal (TA464) on bisphosphonate use in osteoporosis.
Results
The NICE appraisal on bisphosphonate use in osteoporosis indicates that treatment with oral bisphosphonates may be instituted at a FRAX 10-year probability of major osteoporotic fracture above 1%. Implementation would mean that all women aged 50 years or older are deemed eligible for treatment, a position that would increase the burden of rare long-term side effects across the population.
Conclusion
Cost-effectiveness thresholds for low-cost interventions should not be used to set intervention thresholds but rather to validate the implementation of clinically driven intervention thresholds.